Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.453
+0.053 (2.22%)
Aug 6, 2026, 10:32 AM EDT - Market open
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
479.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 260.50K | 137.06K | 111.03% |
| Dec 31, 2022 | 123.44K | -2.98M | -96.02% |
| Dec 31, 2021 | 3.10M | 2.40M | 343.92% |
| Dec 31, 2020 | 698.47K | -424.27K | -37.79% |
| Dec 31, 2019 | 1.12M | -2.92M | -72.22% |
| Dec 31, 2018 | 4.04M | 1.98M | 96.07% |
| Dec 31, 2017 | 2.06M | 1.09M | 113.04% |
| Dec 31, 2016 | 967.39K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Prothena Corporation | 57.94M |
| Q32 Bio | 53.74M |
| Prelude Therapeutics | 16.72M |
| Ovid Therapeutics | 7.12M |
| Ocugen | 4.47M |
| ProKidney | 889.00K |
IKT News
- 14 days ago - Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA - TheFly
- 14 days ago - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - GlobeNewsWire
- 20 days ago - Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation - TheFly
- 23 days ago - Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - GlobeNewsWire
- 4 weeks ago - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics initiated with an Outperform at Oppenheimer - TheFly
- 3 months ago - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics Earnings release: Q1 2026 - Filings